media – Page 646 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China

Amgen and Simcere Pharmaceutical Group today announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. The collaboration includes undisclosed biosimilars in the areas of inflammation and oncology.
- Source: Amgen
- 649
- September 28, 2017
biosimilar inflammation Market Views oncology
Merck’s Keytruda resumes regulatory hot streak with stomach cancer approval

Just a few months after Merck’s monster May for Keytruda, which featured three FDA approvals, the New Jersey drugmaker is back with another green light.
- Source: Fiercepharma
- 729
- September 27, 2017
cancer FDA keytruda Merck
Pfizer launches upstart with $103M, phase 3-ready drugs

In a first for the Big Pharma and as part of a new model, Pfizer is taking drugs from its shelves and licensing them to, while investing in, its SpringWorks Therapeutics startup.
- Source: Fiercebiotech
- 582
- September 27, 2017
Clinical Trials Pfizer Series
J&J lines up its 4-in-1 HIV pill for FDA behind rivals from Gilead, GSK

A couple of months after posting positive late-stage data for its quadruplet-in-one-pill for quelling HIV, J&J says it’s filed a marketing application with the FDA ahead of a planned marketing campaign.
- Source: Endpts
- 563
- September 27, 2017
FDA Gilead GSK HIV J&J Market Views
Ddu Attended Pharmed & Healthcare Vietnam 2017 and the China Dental Show 2017

The 17th Vietnam International Exhibition on products, equipment, medical supplies, pharmaceuticals and hospital & rehabilitation equipment is an important contributing activity in Vietnam hosted by the country’s Ministry of Health. The expo is annually organized by the ADPEX JOINT STOCK COMPANY in cooperation with the Central Health Communication & Education Centre, Vietnam Pharmaceutical Companies Association and VIMEDIMEX VN.
- Source: Ddu
- 892
- September 27, 2017
Exhibitions & Activities Pharmed & Healthcare Vietnam Vietnam
FEops closes €6m Series B financing

FEops, a leader in personalized computer modeling for structural heart interventions, announced today that it has secured a 6 million euros investment, led by Valiance, and joined by existing investors Capricorn and PMV.
- Source: medicaldevices-business-review
- 632
- September 26, 2017
heart investment Market Views Series
EU green light for Roche’s Tecentriq

Roche has received European Commission(EC) approval for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab) to treat specific lung and bladder cancers. The green light means that it can be used as monotherapy for people in the EU with previously-treated locally advanced or metastatic non-small cell cancer (NSCLC), or those with metastatic urothelial carcinoma (mUC) who have received a platinum-based chemotherapy or who are ineligible to receive cisplatin chemotherapy.
- Source: Pharmatimes
- 573
- September 26, 2017
bladder cancer Company Insight immunotherapy lung
FDA approves Abiomed’s new pump for right heart failure

Abiomed has received pre-market approval (PMA) from the US Food and Drug Administration (FDA) for its Impella RP heart pump.
- Source: medicaldevice-network
- 524
- September 26, 2017
FDA heart pump New Approvals PMA
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients

Merck, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.
- Source: Merck
- 557
- September 25, 2017
adenocarcinoma anti-PD-1 GEJ keytruda New Approvals
MIT’s new injection tech delivers multiple vaccines with one poke

Regardless of what it’s protecting you against, few people would likely say that getting a vaccine injection is an altogether enjoyable vaccine. Fortunately, engineers at the Massachusetts Institute of Technology are coming to the rescue with a new 3D fabrication technique that could allow for multiple doses of a drug or vaccine to be delivered to a patient over an extended period of time — with just one jab needed.
- Source: digitaltrends
- 747
- September 25, 2017
Company Insight fabrication needle-phobic vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.